Search

Background and aims Prohibitions on producing, distributing and selling cannabis are loosening in various jurisdictions around the world. This paper describes the diversification of cannabis supply laws and discusses the challenges to and opportunities for learning from these changes. Methods We document changes in cannabis supply laws that de jure legalized cannabis production for medical and/or non-medical purposes (excluding industrial hemp) in Australasia, Europe, North America and South America. We also highlight challenges to evaluating these legal changes based on our experiences studying cannabis laws and policies in the United States. Findings As of August 2016, two countries have passed laws to legalize large-scale cannabis production for non-medical purposes at the national (Uruguay) or subnational level (four US states). At least nine other countries legally allow (or will soon allow) cannabis to be supplied for medicinal purposes. Most of the changes in cannabis supply laws have occurred since 2010. The data available in most countries are inadequate for rigorously evaluating the changes in cannabis supply laws. Conclusion The evidence base for assessing changes in cannabis supply laws remains weak. Efforts should focus upon collecting information about quantities consumed and market transactions as well as validating self-report surveys. [ABSTRACT FROM AUTHOR]

Background and Aims: Eleven US states and the District of Columbia have legalized the non‐medical use of marijuana. Public marijuana smoking is generally prohibited, although some states have considered exemptions. This study assessed attitudes about public marijuana smoking, perceptions of harm from marijuana second‐hand smoke (SHS) and self‐reported marijuana SHS exposure. Design Internet panel survey fielded in June–July 2018. Setting: United States. Participants: US adults aged ≥ 18 years (n = 4088). Measurements Current (past‐30 day) tobacco product use, current marijuana use, opinions about public indoor marijuana smoking, perceptions of harm from marijuana SHS and self‐reported past‐7 day exposure to marijuana SHS in public indoor or outdoor areas were assessed. Weighted prevalence estimates were computed and correlates were assessed using logistic and multinomial regression. Findings Overall, 27.4% [95% confidence interval (CI) = 25.7, 29.1] of adults reported past‐week marijuana SHS exposure in indoor and/or outdoor public areas; younger adults, blacks, Hispanics, those in the Northeast or West, and current marijuana and/or tobacco users were more commonly exposed (Ps < 0.0001). More than half of adults (52.4%; 95% CI = 50.7, 54.2) regarded marijuana SHS as harmful, and most (81.0%; 95% CI = 79.5, 82.4) opposed public marijuana smoking. Correlates of favoring public marijuana smoking included being male, younger (Ps < 0.01), black or Hispanic, past‐month tobacco and/or marijuana users and perceiving no/low harm from marijuana SHS (Ps < 0.0001). Conclusion: While one in four US adults report recent marijuana second‐hand smoke exposure, a majority believe marijuana second‐hand smoke is harmful and most oppose public marijuana smoking. [ABSTRACT FROM AUTHOR]

The authors discuss the failure of a referendum to legalize cannabis in New Zealand in 2020. They state that there were questions on if the Cannabis Legalization and Control Bill (CLCB) would have been able to reduce cannabis use over time through a commercial market and question if the referendum's defeat was due to concerns about cannabis legalization in general or about concerns about the CLCB. They comment on how the black market can pressure legal competition to lower prices.

Harmonizing global data collection on cannabis use is vital, as laws and policies are rapidly evolving. A similar need exists for measurement of medical cannabis use which, at least in the United States, occurs outside medical systems and medical record-keeping -- ultimately putting patients at risk [ABSTRACT FROM AUTHOR]

This article presents an editorial in which the authors comment on the legal aspects of cannabis use in Europe. They discuss the inconsistencies associated with punishments related to the use of cannabis as well as other psychoactive substances, citing data from the European Monitoring Centre for Drugs and Drug Addiction.

Aims To describe patterns of cannabis use, the degree of overlap between medicinal and recreational users, and their differential use patterns, modes of consumption and sources of cannabis. Design An ongoing probability-based internet panel maintained by the market research firm GfK Group. Setting Households in Colorado, Washington, Oregon and New Mexico, USA. Participants A total of 2009 individuals from Washington ( n = 787), Oregon ( n = 506), Colorado ( n = 503) and New Mexico ( n = 213). Post stratification sampling weights were provided so that estimates could be made representative of the household population in each of these states. Respondents were aged between 18 and 91 years, with a mean age of 53 years. Methods We compare patterns of cannabis consumption for medicinal and recreational users as well as simultaneous use of alcohol and cannabis. We also examine the extent to which patterns of use differ across states that chose to legalize ( Washington and Colorado) and those that did not ( New Mexico and Oregon). Findings Rates of life-time medical cannabis use are similar in Colorado and Washington (8.8% and 8.2%) but lower in Oregon and New Mexico (6.5% and 1%). Recreational use is considerably higher than medical use across all states (41%), but highest in Oregon and Washington. Approximately 86% of people who report ever using cannabis for medicinal purposes also use it recreationally. Medical users are more likely to vaporize and consume edibles and report a higher amount (in grams) consumed, and spend more money per month than recreational users. Individuals who use cannabis do not commonly use it with alcohol, irrespective of whether they are consuming cannabis recreationally or medically. Fewer than one in five recreational users report simultaneous use of alcohol and cannabis most or all of the time and fewer than 3% of medicinal users report frequent simultaneous use of alcohol and cannabis. Conclusions In the United States, the degree of overlap between medicinal and recreational cannabis users is 86%. Medicinal and recreational cannabis users favor different modes and amounts of consumption. Only a small proportion (12%) of cannabis users usually consume cannabis and alcohol simultaneously, while concurrent use is common among recreational users. [ABSTRACT FROM AUTHOR]

The article examines the legalization of cannabis in Washington State. Topics examined include how the legalization is emerging with the reduced criminalization of users, how the legalization, known as Initiative 502 (I-502) passed on November 6, 2012, and the state's focus upon science-based public education and youth-focused prevention.

A letter to the editor is presented discussing how cannabis laws influence political repression in Egypt, Tunisia, and Morocco.